Agenus (NASDAQ:AGEN) Shares Cross Above 200 Day Moving Average – Should You Sell?

Agenus Inc. (NASDAQ:AGEN) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.67 and traded as high as $4.30. Agenus shares last traded at $4.15, with a volume of 1,296,172 shares changing hands.

Wall Street Analyst Weigh In

Several brokerages have commented on AGEN. Zacks Research upgraded Agenus from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th. Finally, Wall Street Zen raised shares of Agenus from a “hold” rating to a “buy” rating in a report on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

Agenus Price Performance

The firm has a market cap of $185.47 million, a P/E ratio of -10.50 and a beta of 1.60. The company’s 50 day moving average is $3.37 and its two-hundred day moving average is $3.67.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $1.83. Agenus had a negative return on equity of 7.65% and a negative net margin of 2.67%.The firm had revenue of $34.20 million for the quarter, compared to analyst estimates of $28.10 million. Research analysts predict that Agenus Inc. will post -12.55 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. EP Wealth Advisors LLC bought a new position in Agenus in the fourth quarter worth $31,000. Jump Financial LLC bought a new stake in Agenus in the 2nd quarter valued at $55,000. Traynor Capital Management Inc. bought a new stake in Agenus in the 3rd quarter valued at $50,000. R Squared Ltd acquired a new position in shares of Agenus in the 4th quarter valued at $41,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Agenus in the 3rd quarter valued at $54,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.